CA2763819A1 - Pure peg-lipid conjugates - Google Patents

Pure peg-lipid conjugates Download PDF

Info

Publication number
CA2763819A1
CA2763819A1 CA2763819A CA2763819A CA2763819A1 CA 2763819 A1 CA2763819 A1 CA 2763819A1 CA 2763819 A CA2763819 A CA 2763819A CA 2763819 A CA2763819 A CA 2763819A CA 2763819 A1 CA2763819 A1 CA 2763819A1
Authority
CA
Canada
Prior art keywords
peg
glycerol
lipid
acid
glycol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2763819A
Other languages
English (en)
French (fr)
Inventor
Nian WU
Brian Keller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2763819A1 publication Critical patent/CA2763819A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L63/00—Compositions of epoxy resins; Compositions of derivatives of epoxy resins
    • C08L63/10—Epoxy resins modified by unsaturated compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Polyethers (AREA)
CA2763819A 2009-06-02 2010-06-01 Pure peg-lipid conjugates Abandoned CA2763819A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21762709P 2009-06-02 2009-06-02
US61/217,627 2009-06-02
US28406509P 2009-12-12 2009-12-12
US61/284,065 2009-12-12
PCT/US2010/001590 WO2010141069A2 (en) 2009-06-02 2010-06-01 Pure peg-lipid conjugates

Publications (1)

Publication Number Publication Date
CA2763819A1 true CA2763819A1 (en) 2010-12-09

Family

ID=43298359

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2763819A Abandoned CA2763819A1 (en) 2009-06-02 2010-06-01 Pure peg-lipid conjugates

Country Status (15)

Country Link
US (1) US20110040113A1 (enExample)
EP (1) EP2437756A2 (enExample)
JP (1) JP2012528857A (enExample)
KR (1) KR20120039564A (enExample)
CN (1) CN102665685A (enExample)
AP (1) AP2012006053A0 (enExample)
AU (1) AU2010257181A1 (enExample)
BR (1) BRPI1010175A2 (enExample)
CA (1) CA2763819A1 (enExample)
CL (1) CL2011003049A1 (enExample)
CO (1) CO6511284A2 (enExample)
IL (1) IL216719A0 (enExample)
MX (1) MX2011012823A (enExample)
WO (1) WO2010141069A2 (enExample)
ZA (1) ZA201109366B (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9393315B2 (en) 2011-06-08 2016-07-19 Nitto Denko Corporation Compounds for targeting drug delivery and enhancing siRNA activity
US20120202890A1 (en) * 2011-02-08 2012-08-09 Nian Wu Polymer-carbohydrate-lipid conjugates
WO2012122144A1 (en) * 2011-03-07 2012-09-13 Wu Nian Highly monodisperse branched peg-lipid conjugates
US10196637B2 (en) 2011-06-08 2019-02-05 Nitto Denko Corporation Retinoid-lipid drug carrier
US8883177B2 (en) * 2011-06-28 2014-11-11 Nian Wu Pharmaceutical compositions for parenteral administration
JP6051758B2 (ja) * 2011-10-17 2016-12-27 日油株式会社 ジアシルグリセロールと結合した分岐型ポリエチレングリコール、その製造方法およびポリエチレングリコール修飾リポソーム
ES2881671T3 (es) * 2012-08-21 2021-11-30 Opko Pharmaceuticals Llc Formulaciones de liposomas
US11458199B2 (en) 2012-08-21 2022-10-04 Opko Pharmaceuticals, Llc Liposome formulations
WO2014032026A1 (en) 2012-08-24 2014-02-27 Mitra Ashim K Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions
WO2015021044A1 (en) * 2013-08-05 2015-02-12 University Of Rochester Compositions and methods for stimuli-responsive release of a therapeutic agent
JP6646578B2 (ja) * 2013-12-05 2020-02-14 ウー, ニエンWU, Nian 薬物転送技術のための高分子−炭水化物共役体
ES2708360T3 (es) * 2013-12-20 2019-04-09 Hoffmann La Roche Compuestos que comprenden uno o más dominios hidrófobos y un dominio hidrófilo que comprende restos de PEG, útiles para unir células
EP3084433B1 (en) 2013-12-20 2020-03-18 Roche Diagnostics GmbH Method of immobilizing a cell on a support using compounds comprising a polyethylene glycol moiety
JP6461973B2 (ja) * 2013-12-20 2019-01-30 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ２以上の疎水性ドメインおよびｐｅｇ部分を含む親水性ドメインを含む化合物の、細胞の安定化のための使用
EP3229842B1 (en) 2014-12-08 2022-07-06 The Board of Regents of The University of Texas System Lipocationic polymers and uses thereof
US10064954B2 (en) * 2015-06-23 2018-09-04 Nian Wu Polymer-cyclodextrin-lipid conjugates
CN108271360B (zh) 2015-09-14 2023-01-24 得克萨斯州大学系统董事会 亲脂阳离子树枝状聚合物及其用途
PL3373976T3 (pl) 2015-11-10 2024-06-24 Sun Pharmaceutical Industries Limited Preparaty do stosowania miejscowego i ich zastosowanie
CA3007955A1 (en) 2015-12-10 2017-06-15 Modernatx, Inc. Lipid nanoparticles for delivery of therapeutic agents
CN106905120B (zh) * 2015-12-21 2020-04-28 北京键凯科技股份有限公司 Y型多缩乙二醇衍生物及其制备方法
MX2018010395A (es) 2016-02-29 2018-11-29 Sun Pharma Global Fze Formulaciones topicas que contienen cliclosporina y usos de las mismas.
US20170354672A1 (en) 2016-05-16 2017-12-14 The Board Of Regents Of The University Of Texas System Compositions for the delivery of trna as nanoparticles and methods of use therewith
AU2017267634C1 (en) 2016-05-16 2022-05-26 The Board Of Regents Of The University Of Texas System Cationic sulfonamide amino lipids and amphiphilic zwitterionic amino lipids
WO2018170270A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Varicella zoster virus (vzv) vaccine
US11905367B2 (en) 2018-03-20 2024-02-20 Nof Corporation Branched monodispersed polyethylene glycol, intermediate and methods for producing same
EP3778703B1 (en) * 2018-03-29 2022-08-03 NOF Corporation Method for purifying trityl group-containing monodispersed polyethylene glycol
WO2019191597A1 (en) * 2018-03-30 2019-10-03 The Board Of Regents Of The University Of Oklahoma Very long chain saturated fatty acid compounds, compositions containing same, and methods of use
US12357580B2 (en) 2018-06-19 2025-07-15 The Board Of Regents Of The University Of Texas System Lipid nanoparticle compositions for delivery of mRNA and long nucleic acids
GB2592504B (en) 2018-09-04 2023-02-15 Univ Texas Compositions and methods for organ specific delivery of nucleic acids
EP3846822A4 (en) 2018-09-04 2022-07-06 The Board Of Regents Of The University Of Texas System COMPOSITIONS AND METHODS FOR ORGAN-SPECIFIC DELIVERY OF NUCLEIC ACIDS
AU2019345067A1 (en) 2018-09-19 2021-04-08 Modernatx, Inc. High-purity peg lipids and uses thereof
JP6805385B1 (ja) * 2020-08-31 2020-12-23 ジェイ−ネットワーク，インコーポレイテッド 表皮内の保湿関連物質の発現増強剤
CN116615235A (zh) 2020-10-09 2023-08-18 得克萨斯州大学系统董事会 融合前稳定的hmpv f蛋白
JP6860739B1 (ja) * 2020-11-20 2021-04-21 ジェイ−ネットワーク，インコーポレイテッド 表皮内の抗酸化物質の発現増強剤
WO2022131220A1 (ja) * 2020-12-15 2022-06-23 東洋紡株式会社 ポリエステル樹脂
CN114685778B (zh) * 2020-12-30 2023-10-17 苏州艾博生物科技有限公司 长循环阳离子脂质体的合成方法
CN117157101A (zh) 2021-02-08 2023-12-01 德克萨斯大学系统董事会 不饱和的树枝状聚合物组合物、有关的制剂、及其使用方法
KR20230175196A (ko) 2021-03-23 2023-12-29 리코드 테라퓨틱스, 인크. 폴리뉴클레오티드 조성물, 관련된 제제, 및 이의 사용 방법
WO2022226344A1 (en) 2021-04-22 2022-10-27 The Board Of Regents Of The University Of Texas System All-in-one dendrimer-based lipid nanoparticles enable precise hdr-mediated gene editing in vivo
CN114276535B (zh) 2021-06-30 2022-06-21 天津键凯科技有限公司 聚乙二醇脂质及其应用
CN113461929B (zh) * 2021-07-13 2023-04-21 浙江倍合德制药有限公司 一种tpgs系列产品的精制提纯方法
CN116410460B (zh) * 2021-12-29 2025-08-05 辅必成（上海）医药科技有限公司 一种1,2-二肉豆蔻酰-rac-甘油-3-甲氧基聚乙二醇2000的制备方法
CN114507342B (zh) * 2022-03-18 2024-03-19 江苏东南纳米材料有限公司 一种1,2-二肉豆蔻酰-rac-甘油-3-甲氧基聚乙二醇及其中间体的制备方法
EP4504265A1 (en) * 2022-04-05 2025-02-12 Capstan Therapeutics, Inc. Peg-lipids and lipid nanoparticles
CN114524943B (zh) * 2022-04-22 2022-09-16 天津凯莱英制药有限公司 聚乙二醇-甘油衍生物及其中间体各自的制备方法
CN117003807A (zh) * 2022-04-28 2023-11-07 北京科兴中维生物技术有限公司 一种结构脂质化合物及其制备方法和用途
JP2025539101A (ja) * 2022-11-15 2025-12-03 エボニック オペレーションズ ゲーエムベーハー ポリオキシアルキレンがｃ１～ｃ３－アルキルオキシメチル側鎖を有するポリ（エチレンオキシド）である、ポリオキシアルキレン－１，２－ジミリストイル－グリセロール化合物
EP4630057A1 (en) 2022-12-08 2025-10-15 Recode Therapeutics, Inc. Lipid nanoparticle compositions and uses thereof
EP4648796A2 (en) 2023-01-09 2025-11-19 Board of Regents, The University of Texas System Prefusion-stabilized human parainfluenza virus 3 f proteins
CN116178733B (zh) * 2023-03-03 2023-08-01 浙江博美生物技术有限公司 一种基于三官能团氨基酸的支化单分散peg衍生物、制备方法和应用
US12553042B2 (en) 2023-12-01 2026-02-17 Recode Therapeutics, Inc. Method for quantifying an amount of capped messenger RNA
US12364773B2 (en) 2023-12-01 2025-07-22 Recode Therapeutics, Inc. Lipid nanoparticle compositions and uses thereof
US12539279B2 (en) 2023-12-11 2026-02-03 The Governing Council Of The University Of Toronto Supramolecular ionizable lipid molecules with heteroatomic tuning for nucleic acid delivery
WO2025137646A1 (en) 2023-12-22 2025-06-26 Recode Therapeutics, Inc. Gene editing methods and compositions for treating cystic fibrosis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827533A (en) * 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
US7141552B2 (en) * 2000-01-10 2006-11-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases
CN1882693B (zh) * 2003-09-15 2012-08-15 普洛体维生物治疗公司 聚乙二醇修饰的脂质化合物及其应用
WO2006007712A1 (en) * 2004-07-19 2006-01-26 Protiva Biotherapeutics, Inc. Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents
CA3218940A1 (en) * 2004-11-12 2006-05-18 Cambridge University Technical Services Ltd. Methods and means related to cancer stem cells
CN101909581B (zh) * 2007-11-14 2012-11-14 加利福尼亚大学董事会 固醇修饰的两亲脂质

Also Published As

Publication number Publication date
MX2011012823A (es) 2012-06-25
KR20120039564A (ko) 2012-04-25
JP2012528857A (ja) 2012-11-15
CN102665685A (zh) 2012-09-12
WO2010141069A2 (en) 2010-12-09
ZA201109366B (en) 2012-08-29
US20110040113A1 (en) 2011-02-17
IL216719A0 (en) 2012-02-29
CL2011003049A1 (es) 2012-07-13
WO2010141069A3 (en) 2012-04-12
BRPI1010175A2 (pt) 2016-03-29
AU2010257181A1 (en) 2012-01-12
EP2437756A2 (en) 2012-04-11
CO6511284A2 (es) 2012-08-31
AP2012006053A0 (en) 2012-02-29

Similar Documents

Publication Publication Date Title
AU2010257181A1 (en) Pure PEG-lipid conjugates
US20120232169A1 (en) Highly monodisperse branched peg-lipid conjugates
US6294697B1 (en) Discrete-length polyethylene glycols
US9175027B2 (en) Polymer-carbohydrate-lipid conjugates
AU784395B2 (en) Taxane prodrugs
CN102573913B (zh) 可生物降解的基于聚乙二醇的水不溶性水凝胶
ES2407979T3 (es) Copolímeros de bloques de poli(éter-anhídrido) funcionalizados
CZ2002928A3 (cs) Taxanová proléčiva
JPH10513187A (ja) 高分子量のポリマーを基剤とするプロドラッグ
EP4066860A1 (en) Polyethylene glycol conjugated drug, and preparation method therefor and use thereof
CA2932123A1 (en) Polymer-carbohydrate conjugates for drug delivery technology
US8304565B2 (en) PEG-lipid conjugates for liposomes and drug delivery
WO2021213492A1 (zh) 一类载药的大分子及其制备方法
JP3538606B2 (ja) パクリタキセルまたはその誘導体の残基を含む水溶性プロドラッグ化合物、その製造方法及びそれを含む薬剤組成物
WO2011139343A2 (en) Amino acid linked peg-lipid conjugates
Yue et al. Synthesis and characterization of G5 PAMAM dendrimer containing daunorubicin for targeting cancer cells
US20080286351A1 (en) Pegylated Cardiolipin Analogs, Methods of Synthesis, and Uses Thereof
WO2024131717A1 (zh) 一种阳离子脂质材料的制备及应用
EP3697446A1 (en) Macromolecular platform for targeting scavenger receptor a1
US11952461B2 (en) Siloxy polyethylene glycol and derivatives thereof
WO2026067609A1 (zh) 靶向配体修饰的聚乙二醇化脂质，相关的组合物及其应用
JP2026515027A (ja) ポリマー－薬物複合体、その中間体及びその使用
WO2025137256A1 (en) Polyoxazoline-carbohydrate-lipid conjugates
WO2004092205A1 (en) Hydroxy-substituted-20-acyloxy-camptothecin polymer derivatives and use of the same for the manufacture of a medicament

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20160601